Producing an Anti-β2 Integrin MAb By a Hybridoma Cell Line in a 2-Liter Stirred-Tank BioreactorProducing an Anti-β2 Integrin MAb By a Hybridoma Cell Line in a 2-Liter Stirred-Tank Bioreactor
SLASH TIME FROM BENCH TO BEDSIDE: Cutting-edge biomanufacturing for mAbs, vaccines, and advanced therapies. Bright ideas, bold science, and big innovations—delivering efficiency, precision, and quality through every phase of bioprocessing.